Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 8/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161705 | 0.93 | CYP2C9 (0.87) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL8476895 | 0.88 | CYP2C9 (0.63) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5161367 | 0.86 | CYP2C9 (1.00) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5159376 | 0.84 | CYP2C9 (0.89) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5161332 | 0.83 | CYP2C9 (0.78) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5157966 | 0.82 | CYP2C9 (0.81) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL27545188 | 0.82 | CYP2C9 (0.52) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5157415 | 0.81 | CYP2C9 (0.73) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7487055 | 0.80 | CYP2C9 (0.73) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL5161736 | 0.79 | CYP2C9 (0.71) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1133474-B1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1133474-A4 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1133474-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-19 | — | — | EP | claimed |
| US-6184231-B1 | NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION | BRISTOL-MYERS SQUIBB | 2001-02-06 | — | — | US | claimed |
| WO-2000034244-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-15 | — | — | WO | claimed |
| EP-1133474-B1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1133474-A4 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1133474-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6184231-B1 | NEUROPROTECTANTS; TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, TRAUMATIC BRAIN INJURY, SEXUAL DYSFUNCTION | BRISTOL-MYERS SQUIBB | 2001-02-06 | — | — | US | disclosed |
| WO-2000034244-A1 | 3-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |